• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Emergency

Intra-arterial thrombectomy is associated with improved functional outcomes in stroke patients

byThomas SuandDeepti Shroff
June 11, 2020
in Emergency, Neurology
Reading Time: 3 mins read
Stroke associated with acute and persistent cognitive decline
Share on FacebookShare on Twitter

1. Stroke patients who received endovascular treatment plus standard medical treatment in the public care system in Brazil showed significantly less severe disability at 90 days versus those who received standard care alone.

2. Asymptomatic cranial hemorrhage was judged to have occurred nearly twice as frequently in the thrombectomy group, but the incidence of symptomatic cranial hemorrhage was similar between groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: While thrombectomy has been shown to be highly effective in treating large-vessel occlusions, this procedure has yet to gain traction in lower-income countries with limited healthcare resources because of its high cost. This study conducted in Brazil aimed to assess the utility and feasibility of incorporating endovascular treatment into the country’s public health care system. Patients who received thrombectomy were found to have a significantly better distribution of scores on the modified Rankin Scale of Neurologic Deficit compared to those who received standard thrombolytic care, a finding that resulted in the early termination of the trial. Immediate substantial reperfusion was observed in over three quarters of patients who received thrombectomy; the thrombectomy group also had superior target-vessel recanalization at 24 hours. No between-group differences were observed in the overall incidence or category breakdown of symptomatic intracranial hemorrhage. These improvements came at an average cost of roughly $8000 USD per patient. A major obstacle associated with this study was a dearth of imaging resources that led to delays in treatment as well as a potential overestimation of adverse events. While overall mortality was higher than in previous trials in higher-income countries, the relative benefits shown in this study support the adoption of endovascular stroke treatment in developing regions.

Click here to read the study, published today in NEJM

Relevant Reading: Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke

RELATED REPORTS

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

Intra-arterial alteplase after thrombectomy improves three-month functional recovery in large vessel stroke

Thrombectomy may improve functional independence in acute ischemic stroke with medium vessel occlusion

In-Depth [randomized controlled trial]: This multicenter open-label trial involved patients with occlusion of the intracranial internal carotid artery or the first segment of the middle cerebral artery that could be treated within 8 hours after symptom onset. Patients were classified by age, baseline NIHSS score, use of alteplase, occlusion site, and participating center and assigned in a 1:1 ratio to receive either thrombectomy plus standard care or standard care alone according to Brazilian Stroke Society and American Heart Association guidelines. Conducted after 174 patients had reached 90 days of follow up, an interim analysis for overwhelming efficacy showed an adjusted common odds ratio for a better distribution of Rankin scores of 2.24 (95% confidence interval [CI], 1.30 to 3.88; P=0.004). Inclusion of data from all 211 patients who had been enrolled by this point shifted the odds ratio slightly further in favor of thrombectomy (odds ratio [OR], 2.28; 95% CI, 1.41 to 3.69; P=0.001). Reperfusion of over 50% of the affected territory was achieved immediately following thrombectomy in 91 of 111 patients (82%), but asymptomatic intracranial hemorrhage occurred twice as frequently in this group (51.4% vs 24.5%; OR, 3.24; 95% CI, 1.77 to 6.01). However, symptomatic intracranial hemorrhage occurred in 4.5% of patients in both groups, and 90-day mortality appeared to be independent of treatment regimen as well.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ischemic strokereperfusionstrokethrombectomy
Previous Post

Migraines with aura linked to increased cardiovascular disease risk in women

Next Post

USPSTF Update: Screening adults for unhealthy drug use has moderate net benefit

RelatedReports

Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
No obesity paradox found between BMI, stroke, and death
Neurology

Intra-arterial alteplase after thrombectomy improves three-month functional recovery in large vessel stroke

May 26, 2026
No obesity paradox found between BMI, stroke, and death
Neurology

Thrombectomy may improve functional independence in acute ischemic stroke with medium vessel occlusion

May 26, 2026
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Weekly Rewinds

2 Minute Medicine Rewind April 20, 2026

April 20, 2026
Next Post
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

USPSTF Update: Screening adults for unhealthy drug use has moderate net benefit

#VisualAbstract: Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

#VisualAbstract: Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

#VisualAbstract: Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19

#VisualAbstract: Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Gepotidacin (Blujepa) is safe and effective in women with uncomplicated urinary tract infections
  • Most routine blood tests do not require prolonged fasting
  • Pairing cardiac magnetic resonance with electrocardiograms (ECGs) improved artificial intelligence (AI) assessments of cardiovascular diseases
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.